MedPath

THE COMPARATIVE STUDY OF EFFICACY BETWEEN CREAM CONTAINING SPENT GRAIN WAX, SHEA BUTTER, ARGANIA SPINOSA KERNEL OIL, TAPIOCA STARCH AND 1% HYDROCORTISONE CREAM IN THE TREATMENT AND PREVENTION OF INTERTRIGO

Phase 3
Completed
Conditions
Intertigo
Registration Number
TCTR20200719001
Lead Sponsor
Zuellig Pharma CO., Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
58
Inclusion Criteria

Participants must be one month to sixty years old before the time of study recruitment and had one or more erythematous rashes at intertriginous areas. These lesions have to be performed necessary tests or diagnosed by dermatologists as intertrigo.

Exclusion Criteria

Other common intertriginous rashes were excluded, such as erythrasma by clinical and Wood’s lamp examination, candidiasis by clinical and potassium hydroxide preparation. Contact dermatitis, atopic dermatitis, inverse psoriasis, and seborrheic dermatitis were also excluded by clinical and history taking. Furthermore, subjects who have a history of allergic to corticosteroid, STIMU-TEX AS, or other ingredients in our creams should not participate in this study. In terms of safety, pregnant or lactated women also excluded. Topical and systemic anti-inflammatory agents like corticosteroid, NSAIDs, or antihistamine must stop before starting the protocol for two weeks and four weeks, respectively.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Erythema 0,1,2 and 4 week Visual assessment of erythema
Secondary Outcome Measures
NameTimeMethod
Pruritus 0,1,2 and 4 week Numerical rating scale,Excoriation 0,1,2 and 4 week Visual assessment of excoriation,Quality of life 0 and 4 week Dermatology Life Quality Index,Satisfaction 0 and 4 week 5 scale rating,Adverse events 1,2 and 4 week Causality assessment
© Copyright 2025. All Rights Reserved by MedPath